Prognostic value of renal fractional flow reserve in blood pressure response after renal artery stenting (PREFER study)

Cardiol J. 2013;20(4):418-22. doi: 10.5603/CJ.2013.0101.

Abstract

Background: The aim of our study was to determine a potential relationship between resting translesional pressures ratio (Pd/Pa ratio), renal fractional flow reserve (rFFR) and blood pressure response after renal artery stenting.

Methods: Thirty five hypertensive patients (49% males, mean age 64 years) with at least 60% stenosis in angiography, underwent renal artery stenting. Translesional systolic pressure gradient (TSPG), Pd/Pa ratio (the ratio of mean distal to lesion and mean proximal pressures) and hyperemic rFFR - after intrarenal administration of papaverine - were measured before stent implantation. Ambulatory blood pressure measurements (ABPM) were recorded before the procedure and after 6 months. The ABPM results were presented as blood pressure changes in subgroups of patients with normal (≥ 0.9) vs. abnormal (< 0.9) Pd/Pa ratio and normal (≥ 0.8) vs. abnormal (< 0.8) rFFR.

Results: Median Pd/Pa ratio was 0.84 (interquartile range 0.79-0.91) and strongly correlated with TSPG (r = -0.89, p < 0.001), minimal lumen diameter (MLD; r = 0.53, p < 0.005) and diameter stenosis (DS; r = -0.51, p < 0.005). Median rFFR was 0.78 (0.72-0.82). Similarly, significant correlation between rFFR and TSPG (r = -0.86, p < 0.0001), as well as with MLD (r = 0.50, p < 0.005) and DS (r = -0.51, p < 0.005) was observed. Procedural success was obtained in all patients. Baseline Pd/Pa ratio and rFFR did not predict hypertension response after renal artery stenting. Median changes of 24-h systolic/diastolic blood pressure were comparable in patients with abnormal vs. normal Pd/Pa ratio (-4/-3 vs. 0/2 mm Hg; p = NS) and with abnormal vs. normal rFFR (-2/-1 vs. -2/-0.5 mm Hg, respectively).

Conclusions: Physiological assessment of renal artery stenosis using Pd/Pa ratio and papaverine- induced renal fractional fl ow reserve did not predict hypertension response after renal artery stenting.

Trial registration: ClinicalTrials.gov NCT01128933.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Aged
  • Angioplasty / instrumentation*
  • Blood Pressure Monitoring, Ambulatory
  • Blood Pressure*
  • Female
  • Humans
  • Hypertension, Renovascular / diagnosis
  • Hypertension, Renovascular / physiopathology
  • Hypertension, Renovascular / therapy*
  • Male
  • Middle Aged
  • Multidetector Computed Tomography
  • Papaverine
  • Predictive Value of Tests
  • Renal Artery Obstruction / diagnosis
  • Renal Artery Obstruction / physiopathology
  • Renal Artery Obstruction / therapy*
  • Renal Circulation*
  • Stents*
  • Time Factors
  • Treatment Outcome
  • Ultrasonography, Doppler, Duplex
  • Vasodilator Agents

Substances

  • Vasodilator Agents
  • Papaverine

Associated data

  • ClinicalTrials.gov/NCT01128933